Colon cancer screening is only effective if you complete the test. With 53,000 Americans expected to die from colon cancer in ...

Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal ...

With colon cancer rates rising, advocates hope a newly approved blood test screening can help more people catch it early.

According to Guardant’s website, Medicare Part B (Medical Insurance) covers a blood-based biomarker screening test to check for colorectal cancer if the individual is between the ages of 45–85, shows ...

Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA ApprovalBERKELEY ...

The in-vitro colorectal cancer screening tests market is set for significant growth, driven by advancements in diagnostics ...

With colon cancer rates rising, advocates hope a newly approved blood test screening can help more people catch it early. “If we find it early, we have a lot more options in treating it,” said Dr.

(RTTNews) - Mainz Biomed N.V. (MYNZ), Thursday announced a collaboration with Quest Diagnostics Inc. (DGX) to commercialize the former's NextGen screening test for colorectal cancer, called ColoAlert ...

Cases of colorectal cancer have been rapidly increasing among young adults, so we spoke to a doctor to get some helpful tips.